Previous 10 | Next 10 |
AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to ‘simuf...
Often, the best investments are the ones most of the market isn't paying attention to. With all eyes focused on coronavirus stocks, it may be a good time for investors to look at the possibilities for progress on other diseases that have plagued us for a lot longer. Alzheimer's, for exa...
Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) ...
Cassava Sciences (SAVA) prices public offering of 9,375,000 shares of its common stock at $0.001/share.Gross proceeds will be ~$75M, excluding the exercise of underwriter’s option to purchase up to an additional 1,406,250 shares.The company intends to use the proceeds to fund the ...
AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced und...
Cassava Sciences (SAVA) -18% after announcing proposed public offering.Shift Technologies (SFT) -18% on Q3 earnings release.IMAC Holdings (IMAC) -17%.EuroDry (EDRY) -15%.Biocept (BIOC) -15% on Q3 earnings release.Creative Realities (CREX) -12% on Q3 ear...
Shares of the clinical-stage biopharma Cassava Sciences (NASDAQ: SAVA) dropped by a whopping 18.5% in after-hours trading Thursday. The drugmaker's stock hit the skids yesterday following the announcement of an underwritten public offering. While the details of the offering have...
Cassava Sciences (SAVA) -18.4% AH, commenced an underwritten public offering of shares; expects to grant underwriters a 30‐day option to purchase up to an additional 15% of shares.Offer size, terms and timing have not been disclosed.Proceeds, if any, will be used for fun...
AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it is commencing an underwritten publi...
Biotech Stocks Take Center Stage On Pfizer’s Vaccine News Biotech stocks certainly have had an interesting year so far. With the initial stock market crash in March 2020, things were certainly bleak. However, if you look at the S&P 500 Health Care index today, it ...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
$126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NE...
2024-05-08 16:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross proceeds of over $125 million from cash-exercises of warrants that were previously distri...